Antihyperlipidemic Drugs Market, By Drug Class (Statins, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, Fibric Acid Derivatives, PCSK9 Inhibitors, Combination, and Others), and By Geography (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa)

Published In : Jul 2023

Code : CMI5992

Pages :160

Formats :

Excel and PDF

Industry : Pharmaceutical

Antihyperlipidemic Drugs MarketSize and Trends

The global antihyperlipidemic drugs market was valued at US$ 12.6 Bn in 2022 and is forecast to reach a value of US$ 22.5 Bn by 2030 at a CAGR of 7.5% between 2023 and 2030. The global antihyperlipidemic drugs market is experiencing strong growth due to the rise in prevalence of hyperlipidemia and surge in sedentary lifestyle across the world. Moreover, increasing demand for antihyperlipidemic drugs and growing geriatric population across the globe is expected to boost the growth of the market. However, factors such as high cost of treatment and lack of awareness among people are expected to hamper the market growth.

Global Antihyperlipidemic Drugs Market Trends:

High demand statin hyperlipidemia drugs is a recent trend

Statins (HMG CoA reductase inhibitors) are prescription medicines that people take to bring their cholesterol down to normal levels. Statins also are safe and effective in reducing triglyceride levels in patients with hypertriglyceridemia. It is the first line of therapy that reduces the risk associated with heart attacks which in turn contributes to the market growth. Systematic review of 75 clinical trials found that rosuvastatin and atorvastatin statins lowered LDL cholesterol by more than 40% (high-intensity statins). This trend is expected to continue over the forecast period.

Increase in awareness among people is another trend

With the increasing awareness among people about the risk of hyperlipidemia and cardiovascular disease, the demand for antihyperlipidemic drugs is also increasing. Hyperlipidemia is one of the important modifiable risk factors for CVDs. Raising public awareness of CVD risks is an important step in reducing CVD burdens. Thus, several healthcare organizations and governments across the globe are increasing public awareness and knowledge about cholesterol and its management. This trend is also expected to continue over the forecast period.